Guarded optimism over esketamine

There is guarded optimism over esketamine, which an FDA panel just recommended for approval. While over 200 studies have definitively shown that ketamine infusions rapidly relieve depression symptoms, more studies need to be done before there is any conclusive evidence esketamine does the same. Esketamine, which is half the ketamine molecule, shows mixed results in the small number of quality studies conducted. Amongst the scientific community debate exists over whether half of the molecule alone provides mood disorder benefits; which half of the molecule, S or R provides benefits; or if half the molecule is as effective as the whole in treating mood disorders.